Clinical trial
Tetrathiomolybdate in Hormone Refractory Prostate Cancer
NCT00150995 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00150995 |
|---|---|
| Title | Tetrathiomolybdate in Hormone Refractory Prostate Cancer |
| Official title | A Phase II Trail of Tetrathiomolybdate in Patients With Hormone Refractory Prostate Cancer |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Tetrathiomolybdate |
| Enrollment | 19 |
| Start date | May 1, 2001 |
| Primary completion | Oct 1, 2003 |
| Completion | Apr 1, 2006 |
| First posted | Sep 8, 2005 |
| Last update posted | Jan 21, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: